Introduction
Vascular endothelial growth factor (VEGF)-targeted agents have contributed to increased success in the treatment of cancer (1), but not all patients benefit from therapy and the prediction of individual benefit remains problematic. The identification of a valid, inexpensive, and easily measurable predictive biomarker of efficacy is of great interest. Numerous antiangiogenic biomarkers have been studied; however, to date no validated biomarker exists for selecting patients for antiangiogenic therapy (1) .
The occurrence of increased blood pressure (BP) with the use of VEGF-targeted agents is widely reported (2, 3) . This effect is usually manageable with dose modification and/or antihypertensive therapy (3) . Systematic meta-analyses report a significantly increased risk of hypertension in cancer patients treated with bevacizumab (4), sunitinib (5) , or sorafenib (6) compared with patients not receiving antiangiogenic therapy. This effect may be attributed to disruption of VEGF-VEGF receptor (VEGFR) signaling. Recent studies suggest that inhibition of VEGFR suppresses nitric oxide production, causing increased vascular resistance and BP.
Further, endothelial cell death induces vascular rarefaction, reduces vascular distensibility, and alters endothelin function (2) .
Axitinib is an oral, potent, and selective inhibitor of VEGFR-1, 2, and 3 currently in phase III development for metastatic renal cell carcinoma (mRCC). A phase I dose-finding study suggested a relationship between axitinib exposure and BP (7) . Data from patients with mRCC indicated that BP increased early during the course of treatment with axitinib (within 1 week in 25% of patients) (8) . Preclinical data show that axitinib rapidly inhibits downstream signaling via the endothelial nitric oxide synthase/protein kinase B pathway implicated in normal vascular homeostasis, suggesting elevated BP during axitinib treatment is related to its inhibitory effects on VEGFR-2 (9). Based on these data, it was hypothesized that drug-induced BP elevation may be an early indicator of drug activity at the desired molecular target, serving as a biomarker of 
Materials and Methods

Patient population and study design
Five phase II multicenter trials evaluating the safety and efficacy of axitinib in multiple solid tumors, including mRCC (two trials) (8, 10) , non-small-cell lung cancer (NSCLC) (11) Manuscript in preparation), and thyroid cancer (12) were analyzed (Table 1) .
Briefly, eligibility criteria common to all five studies included patients aged ≥18 years with histologically or cytologically confirmed malignancy; no pre-existing uncontrolled hypertension, defined by baseline BP >140/90 mm Hg (antihypertensive medications permitted); an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1; and adequate organ function. For these analyses, dBP was selected because it is less labile than systolic BP (sBP), and dBP ≥90 mm Hg is a commonly used criterion for hypertension (13) .
These trials were performed in accordance with the International Conference on Harmonization Good Clinical Practice guidelines, applicable local regulatory requirements and laws, and individual protocols approved by their respective institutional review boards. All patients provided written informed consent.
Treatment
Research. (two BP measurements separated by ≥1 h), axitinib dosing was interrupted until BP was <150/100 mm Hg, and then resumed with the axitinib dose decreased by one level. In cases of persistent or recurrent hypertension following axitinib dose reduction, the axitinib dose was decreased by another level or withheld.
Assessments
Patients underwent physical examinations and laboratory testing at baseline and every 4 weeks thereafter. Patients measured their own BP at least daily and were instructed to contact their physician immediately for sBP >150 mm Hg or dBP >100 mm Hg. For the sorafenib-refractory mRCC study, in-clinic BP measurements were obtained every 2 weeks for six visits and then every 4 weeks. For all other studies, in-clinic BP measurements were obtained every 4 weeks.
Measurements of BP were taken with patients seated and resting for 5 min.
Based upon in-clinic BP measurements, patients were retrospectively stratified into two groups after initiation of axitinib therapy: patients with dBP measurements <90 mm Hg throughout the study (<90 group), and patients with at least one dBP ≥90 mm Hg at any time during the study (≥90 group). For patients with more than one dBP ≥90 mm Hg, the first dBP measurement ≥90 mm Hg was used for these analyses. Median overall survival (OS), median progression-free survival (PFS), objective response rate (ORR), and AEs were evaluated by 
Statistical analysis
Analyses of hazard ratios were conducted using a Cox proportional hazards model (16), with the first onset of dBP ≥90 mm Hg obtained in the clinic treated as a time-dependent covariate.
Thus, a given patient is not accounted for in the dBP ≥90 mm Hg risk set until the first in clinic measurement ≥90 mm Hg is observed. This is in contrast to a fixed covariate Cox proportional hazards model in which a patient would be assigned to the dBP ≥90 mm Hg risk set for the duration of their time on study. This method controls for potential bias resulting from patients living longer and, consequently, having a greater opportunity for dBP ≥90 mm Hg due to an increased number of BP measurements (17). A landmark analysis (18) was conducted using the maximum dBP achieved by week 8 (allowing for two in-clinic BP measurements) to stratify patients into the dBP <90 or ≥90 groups, and assessed OS and PFS from that point forward. All patients dying or progressing, according to the particular end point, prior to the 8-week landmark were excluded from the analyses. Medians of OS and PFS were estimated with Kaplan-Meier methods using time from the 8 week landmark. Response rates were compared using Fisher's exact test. All statistical tests were two-sided at a 5% level of significance. Statistical analyses were performed using SAS ® software (versions 8.2 and 9.1; SAS Institute Inc, Cary, NC, USA).
RESULTS
Research. Of the 230 patients analyzed by stratification group (Table 2 ), 43% (n = 100) were in the <90 group and 57% (n = 130) in the ≥90 group. Median age and gender were similar between these two groups. Median dBP at baseline was significantly higher in the ≥90 group than the <90 group (P < 0.001) irrespective of antihypertensive therapy use at baseline. In the ≥90 group, 65 patients (50%) and 87 patients (67%) exhibited dBP ≥90 at weeks 4 and 8, respectively. More than half of patients in the ≥90 group had a maximum dBP measurement ≥94 mm Hg.
Diastolic blood pressure and efficacy relationships
In a pooled analysis of OS (events, n = 140), there was a significantly lower relative risk of death for patients in the ≥90 group compared with those in the <90 group (hazard ratio [HR] [95% confidence interval (CI)] = 0.55 [0.39, 0.77]; P < 0.001) ( Table 3 ; Fig.) . The pooled analysis demonstrated a 45% reduction in the risk of death for patients in the ≥90 group (Table   4 ). Multivariate analyses, including dBP, baseline PS, dose level, and use of antihypertensive medication in the model, revealed that dBP was an independent predictor of OS, with an HR of 0.676 (95% CI 0.470-0.972; P = 0.036) in favor of the ≥90 group. Similar trends were observed for PFS and ORR (Tables 3, 4 ). In the pooled analysis, PFS was 3.1 months longer for patients in the ≥90 group compared with the <90 group.
Similarly, in the pooled analysis, ORR was significantly higher in the ≥90 group compared with the <90 group (43.9% versus 12.0%; P < 0.001). The greatest tumor response difference by dBP group was observed in patients with cytokine-refractory mRCC (65.6% versus 10.5%, ≥90 versus <90 groups, respectively; P < 0.001). In all five individual trials, the ORR was numerically higher in patients in the ≥90 group compared with the <90 group.
A landmark analysis for OS and PFS measured from 8 weeks after initiation of axitinib therapy supported the overall analyses. For patients in the ≥90 group compared with the <90 group, respectively, the median OS (25. 
Safety and tolerability
Pooled data for single-agent axitinib treatment suggest that grade 3/4 AEs were largely similar between the two dBP groups, with the exception of hypertension, hand-foot syndrome, and arthralgia, which were reported more often in the ≥90 group compared with the <90 group (Table 5 ). In the <90 group, seven patients had an AE of hypertension: two patients had evidence of hypertension as defined by sBP; the remaining five patients may have had home BP measurements that prompted an AE report of hypertension or changes in the in-clinic BP measurement from baseline that were considered hypertension by the investigator but did not meet the dBP ≥90 mm Hg threshold for these analyses.
Discussion
Research. Moreover, studies using the NCI CTCAE grading system may apply inconsistent definitions of grade 2 and 3 hypertension, which are not mutually exclusive and may be subject to interpretation (6) . The threshold of dBP ≥90 mm Hg employed here is commonly used in clinical practice for assessing clinically relevant changes in BP (13, 29) and was also used to assess hypertension as a biomarker of sunitinib efficacy (19). A limitation of this threshold was that patients with a dBP equal to 90 mm Hg at baseline were included (<90 group, 3%; ≥90 group, 7%); thus, dBP of 90 mm Hg in the ≥90 group cannot be definitively characterized as treatmentinduced for these few patients, Furthermore, mean changes in dBP from baseline were not assessed; thus, patients may have developed increased dBP without reaching the ≥90 mm Hg threshold, and the incidence of drug-induced BP elevations may have been underestimated. In and not changes in systolic BP due to less lability in measurement. It is possible that systolic BP may also be a potential biomarker, and such data is being gathered in ongoing trials with axitinib.
Comparisons of survival between treatment response groups are inherently biased, since responders, patients in the ≥90 group in this study, must live long enough for the response to be observed (17, 19, 22). Two valid approaches (17, 19, 22) were used in the current study to minimize this inherent bias. First, the onset of dBP ≥90 mm Hg was treated as a time-dependent variable for modeling OS, PFS, and ORR measured from baseline, which takes into account the temporal relationship between dBP and outcome. For each event, the risk sets are redefined, i.e., a patient will move into the ≥90 group if dBP ≥90 mm Hg was observed in that patient by the time of that event. A patient's exposure status is thus allowed to vary over time. A multivariate model incorporating baseline PS, antihypertensive use, and dose level in addition to the time-dependent dBP covariate also showed dBP to be an independent predictor of OS. Still, it is not possible to completely remove the possible confounding of dosing and antihypertensive therapies with dBP elevation and their effect on OS. Second, a landmark analysis was conducted that evaluated OS and PFS from week 8, based on the maximum dBP achieved at that time. This method corrects for bias by fixing the timepoint for determination of dBP ≥90 mm Hg and observing OS or PFS events from that point forward. In the landmark analysis, median OS and PFS were longer for patients in the ≥90 group compared with the <90 group but this difference did not reach statistical significance. Some statistical power is lost with this method, since patients who died or progressed are excluded, regardless of their respective BP response.
The number of patients evaluated here was small compared with similar studies that reported above, is needed to more fully evaluate dBP ≥90 mm Hg as marker of efficacy during axitinib therapy using landmark analyses.
Initial observations in an axitinib phase I trial (7) suggested that the incidence and severity of elevated BP was dose-dependent. However, preliminary pharmacokineticpharmacodynamic evaluations in mRCC patients suggested dBP ≥90 mm Hg with axitinib therapy was an independent predictor of clinical efficacy and not merely a reflection of higher axitinib drug concentrations (32). Nonetheless, increases in BP during axitinib treatment may be related, in part, to axitinib exposure and may not occur in patients receiving suboptimal doses. 
Despite substantial efforts, identification of a robust and reliable biomarker for antiangiogenic agents has proved elusive. Serial measurements of dBP are convenient and may be useful once therapy is started. Pooled and individual analyses presented here suggest that patients treated with axitinib had a dBP ≥90 mm Hg early during therapy and that dBP ≥90 mm Hg was associated with clinical improvements across multiple tumor types. This retrospective pooled evaluation suggests that dBP may be a simple, reliable, and inexpensive predictive biomarker of efficacy for an angiogenesis inhibitor. Based on these findings, further investigation of dBP as a biomarker of axitinib efficacy is warranted. An ongoing prospective clinical trial of axitinib in patients with mRCC is assessing ambulatory blood pressure and evaluating the relationship between BP and clinical outcome (32).
Research. 
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